Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Residual and recurrent gastrointestinal stromal tumors with KIT mutations: findings at first follow-up CT after imatinib treatment.

AJR. American journal of roentgenology - 1 Aug 2009

Choi Dongil, Yoo Eun Young, Kim Kyoung-Mee, Sohn Tae Sung, Lee Won Jae, Lee Ji Young, Chang Ilsoo

Abstract excerpt

OBJECTIVE: The purpose of this study was to correlate findings on the first follow-up CT after treatment with imatinib in patients with residual or recurrent gastrointestinal stromal tumors (GISTs) with the different types of KIT mutation present at initial resection. CONCLUSION: Residual and recurrent GISTs with KIT mutation of exon 11 deletion more frequently showed both tumor shrinkage and cystic change on...

Topics

Join the communities discussing this publication.

Benzamides
Gastrointestinal Stromal Tumors
Imatinib Mesylate
Neoplasm, Residual
Piperazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Proto-Oncogene Proteins c-kit

Receptor, Platelet-Derived Growth Factor alpha

Splenic Neoplasms

Source

Identifiers

PMID: 19620409
DOI: 10.2214/AJR.08.2106

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Residual and recurrent gastrointestinal stromal tumors with KIT mutations: findings at first follow-up CT after imatinib treatment.PMID 19620409Read ↗

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.Semantic proximity Read ↗

Gastrointestinal stromal tumor after tyrosine kinase inhibition therapy: a review of biopsies of 34 patients with clinically suspected relapse and/or progression of the tumor.Semantic proximity Read ↗

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.Semantic proximity Read ↗

Resistance to treatment in gastrointestinal stromal tumours: what radiologists should know.Semantic proximity Read ↗

[A case report of huge abdominal recurrent tumor of small intestinal GIST after 15 years from the operation with primary lesion].Semantic proximity Read ↗

Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.Semantic proximity Read ↗

Radiographic Versus Pathology-Integrated Response for Assessing Optimal Surgical Timing After Neoadjuvant Imatinib in Patients With Locally Advanced KIT Exon 11-Mutant GIST.Semantic proximity Read ↗

Metabolic pseudo-progression in a patient with metastatic KIT exon 11 GIST after one month of first-line imatinib: a case reportSemantic proximity Read ↗

Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.